Research Paper Volume 15, Issue 23 pp 13646—13654
Cabozantinib prevents AGEs-induced degradation of type 2 collagen and aggrecan in human chondrocytes
Figure 4. Cabozantinib increased type II collagen and aggrecan levels in AGEs-treated SW1353 chondrocytes. SW1353 chondrocytes were stimulated with 100 μg/ml AGEs with or without 10 and 20 μM Cabozantinib for 24 h. The type II collagen and Aggrecan levels were detected by the Western blotting assay (n=6, *, ** P<0.05, 0.01 vs. Control group, #, ## P<0.05, 0.01 vs. AGEs group).